CD86 and familial pancreatic carcinoma: Additionally, comprehensive analysis of pathological staining revealed that anti-CD47 nanobody therapy more effectively reduced the infiltration of F4/80+CD163+ TAMs and increased the infiltration of F4/80+CD86+ TAMs in pancreatic cancer with CCT6A knockdown (Fig. 7E).